536565 TRIMURTHI

Novelix Pharmaceuticals Share Price

₹24.15 +1.15 (5%)

23 Dec, 2024 04:07

SIP TrendupStart SIP in TRIMURTHI

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 5%
  • Over 3 Month + 15.72%
  • Over 6 Month + 27.51%
  • Over 1 Year + 121.56%
SIP Lightning

Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!

Invest Now

Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Novelix Pharmaceuticals Financials

Novelix Pharmaceuticals Technicals

EMA & SMA

Current Price
₹24.15
+ 1.15 (5%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹21.77
  • 50 Day
  • ₹18.92
  • 100 Day
  • ₹16.03
  • 200 Day
  • ₹13.43

Resistance and Support

24.15 Pivot Speed
  • R3 24.15
  • R2 24.15
  • R1 24.15
  • S1 24.15
  • S2 24.15
  • S3 24.15

What's your outlook on Novelix Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Trimurthi Dg.& Pharms. has an operating revenue of Rs. 5.90 Cr. on a trailing 12-month basis. An annual revenue growth of 136% is outstanding, Pre-tax margin of 1% needs improvement, ROE of 0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It has recently broken out of a base in its weekly chart and is trading around 10% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 27 which is a POOR score indicating inconsistency in earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 72 indicates it belongs to a poor industry group of Food-Packaged and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results & Others Inter-alia, 1. To take note of the Certificate of Whole Time Director & Chief Financial Officer of the Company for the quarter and half year ended 30th September 2024.
2024-10-21 To consider issue of Warrants (Revised)
2024-09-02 Others Inter alia, to consider 1. Amendment of Main Objects of the Company. 2. Change in name of the Company. 3. Change in the Registered Office of the Company.
2024-08-08 Quarterly Results
2024-05-28 Audited Results

Novelix Pharmaceuticals F&O

Novelix Pharmaceuticals Shareholding Pattern

66.56%
20.12%
13.32%

About Novelix Pharmaceuticals

  • NSE Symbol
  • TRIMURTHI
  • BSE Symbol
  • 536565
  • ISIN
  • INE314I01036

Similar Stocks to Novelix Pharmaceuticals

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals share price is ₹24 As on 23 December, 2024 | 03:53

The Market Cap of Novelix Pharmaceuticals is ₹24 Cr As on 23 December, 2024 | 03:53

The P/E ratio of Novelix Pharmaceuticals is 1232.1 As on 23 December, 2024 | 03:53

The PB ratio of Novelix Pharmaceuticals is 3.3 As on 23 December, 2024 | 03:53

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23